IMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY) Files An 8-K Other Events
Item 8.01 Other Information.

On September 20, 2017, Imprimis Pharmaceuticals, Inc. (the “Company”) received a shareholder update letter (the “Eton Letter”) from Eton Pharmaceuticals, Inc. (“Eton”). The Eton Letter discusses recent business activities, developments and other updates related to Eton. The Company currently owns three million five hundred thousand (3,500,000) shares of Eton common stock, which is approximately 27% of the equity and voting interests of Eton.

The foregoing is only a brief description of the Eton Shareholder Letter, does not purport to be a complete description of the Eton Letter and is qualified in its entirety by reference to the full text of the document, which is filed as Exhibits 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

(d) Exhibits.

Imprimis Pharmaceuticals, Inc. Exhibit
EX-10.1 2 ex10-1.htm     21925 Field Pkwy,…
To view the full exhibit click here

About IMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY)

Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.